Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

Poster: Comparing Anti-CTLA-4 Effect Across I/O Model Platforms

Distinct Response to CTLA-4 Antibodies by Different Tumors Implicates Different Mechanisms of Action

Davy Xuesong Ouyang, Zhung Wang, Gavin Jiagui Qu, Gang Chen*, Annie Xiaoyu An, Jinping Liu, Leo Liu, Vincent Huang, Jay Liu*, Xin Dong*, Henry Q. Li
*Nanjing Galaxy Biopharmaceutical Co. Ltd.

Poster: Comparing Anti-CTLA-4 Effect Across I/O Model PlatformsNew immunotherapy assessment platforms are needed to progress immuno-oncology agents such as checkpoint inhibitors including CTLA-4. Tumor homograft models and syngeneics can be used to assess mouse surrogate checkpoint inhibitors, with humanized models then needed to evaluate human-specific agents.

We’ve developed immune checkpoint target humanized mice as a cost-effective alternative to complex, fully humanized models. This includes a CTLA-4 model, with humanized CTLA-4 receptors within a functional mouse immune system.

This poster tests different immuno-oncology platforms such as syngeneics, tumor homografts, and our CTLA-4 humanized model with various anti-CTLA-4 antibodies against both mouse and human targets, to explore different mechanisms of sensitivity/resistance.

Read this Poster to Discover:

  • That human and mouse CTLA-4 antibodies have different mechanisms of action

  • That T cells from the humanized CTLA-4 models express hCTLA-4, providing an ideal model to test human-specific agents

  • How tumor homografts and humanized drug target models are particularly useful for investigating the mechanism of action of immunotherapies

Download the Poster Now!

Download Now!

Your privacy is important to us.
We'll never share your information.

SHARE THIS